{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:34:32Z","timestamp":1793900072728,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000381","name":"Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106303","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:11:30Z","timestamp":1738138290000},"page":"106303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The CXCL13 index biomarker predicts success or failure of moderate-efficacy disease-modifying therapies in multiple sclerosis; A real-world study"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-6309","authenticated-orcid":false,"given":"Andrew R.","family":"Pachner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106303_bib0040","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1038\/s41467-023-42682-9","article-title":"Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis","volume":"14","author":"Akesson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2025.106303_bib0018","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/1352458512473362","article-title":"CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions","volume":"19","author":"Alvarez","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106303_bib0019","article-title":"Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures","volume":"1","author":"Alvarez","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106303_bib0028","article-title":"First line treatment failure: predictive factors in a cohort of 863 relapsing remitting MS patients","volume":"48","author":"Ayrignac","year":"2021","journal-title":"Mult\/ Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106303_bib0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ana.25637","article-title":"A 30-year clinical and magnetic resonance imaging observational study of multiple sclerosis and clinically isolated syndromes","volume":"87","author":"Chung","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/13524585231223880","article-title":"Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society","author":"Collongues","year":"2024","journal-title":"Multiple Scleros. (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.msard.2025.106303_bib0033","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2024.0017","article-title":"Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis","author":"Cross","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0023","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2019.01821","article-title":"Central nervous system inflammatory aggregates in the theiler's virus model of progressive multiple sclerosis","volume":"10","author":"DiSano","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106303_bib0010","article-title":"Intrathecally produced CXCL13: a predictive biomarker in multiple sclerosis","volume":"6","author":"DiSano","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106303_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12987-021-00244-5","article-title":"Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on \"Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function","volume":"18","author":"DiSano","year":"2021","journal-title":"Fluids. Barriers. CNS."},{"key":"10.1016\/j.msard.2025.106303_bib0031","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1093\/brain\/awq226","article-title":"Predicting a window of therapeutic opportunity in multiple sclerosis","volume":"133","author":"Ebers","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106303_bib0034","doi-asserted-by":"crossref","first-page":"e81007","DOI":"10.1371\/journal.pone.0081007","article-title":"Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis","volume":"8","author":"Edwards","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2025.106303_bib0017","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1309\/Y5VFF2UAW0RK5W63","article-title":"Cerebrospinal fluid oligoclonal bands in the diagnosis of multiple sclerosis. Isoelectric focusing with IgG immunoblotting compared with high-resolution agarose gel electrophoresis and cerebrospinal fluid IgG index","volume":"120","author":"Fortini","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.msard.2025.106303_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241239740","article-title":"Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry","volume":"17","author":"Frahm","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106303_bib0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-021-10673-9","article-title":"Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study","volume":"269","author":"Hanninen","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0006","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0012","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0039","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1038\/s41598-024-57116-9","article-title":"Treatment satisfaction with disease-modifying therapy is the only predictor of adherence among multiple sclerosis patients from Upper Egypt","volume":"14","author":"Khedr","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106303_bib0037","article-title":"Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis","author":"Klicova","year":"2024","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.msard.2025.106303_bib0032","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment","volume":"129","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106303_bib0008","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0022","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14737175.2023.2208347","article-title":"The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis","volume":"23","author":"Morgan","year":"2023","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.msard.2025.106303_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.607766","article-title":"Ectopic lymphoid follicles in multiple sclerosis: centers for disease control?","volume":"11","author":"Negron","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102281","article-title":"Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13","volume":"44","author":"Olesen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106303_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/1744666X.2021.1886924","article-title":"Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment","volume":"17","author":"Otero-Romero","year":"2021","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106303_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092099","article-title":"The brave new world of early treatment of multiple sclerosis: using the molecular biomarkers CXCL13 and neurofilament light to optimize immunotherapy","volume":"10","author":"Pachner","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.msard.2025.106303_bib0025","first-page":"24","article-title":"The CXCL13 index as a predictive biomarker for activity in clinically isolated syndrome","author":"Pike","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106303_bib0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0029","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40271-015-0136-x","article-title":"Patient preferences for injectable treatments for Multiple sclerosis in the United States: a discrete-choice experiment","volume":"9","author":"Poulos","year":"2016","journal-title":"Patient."},{"key":"10.1016\/j.msard.2025.106303_bib0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/jnnp-2019-322348","article-title":"Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis","volume":"91","author":"Prosperini","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106303_bib0036","first-page":"99","article-title":"Cerebrospinal fluid\u2013physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases","volume":"4","author":"Reiber","year":"1998","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.msard.2025.106303_bib0038","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1590\/0004-282x20160066","article-title":"Knowledge-base for interpretation of cerebrospinal fluid data patterns. Essentials in neurology and psychiatry","volume":"74","author":"Reiber","year":"2016","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106303_bib0007","first-page":"45","article-title":"Effectiveness and safety of early high-efficacy versus escalation therapy in relapsing-remitting multiple sclerosis in Argentina","volume":"45","author":"Rojas","year":"2022","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2025.106303_bib0011","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0027","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/WNL.0000000000002830","article-title":"Assessing response to interferon-beta in a multicenter dataset of patients with MS","volume":"87","author":"Sormani","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106303_bib0030","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/1055-9965.EPI-21-0509","article-title":"Intraindividual long-term immune marker stability in plasma samples collected in median 9.4 years apart in 304 adult cancer-free individuals","volume":"30","author":"Spath","year":"2021","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.msard.2025.106303_bib0005","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective Treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000636","article-title":"An argument for broad use of high efficacy treatments in early multiple sclerosis","volume":"7","author":"Stankiewicz","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106303_bib0014","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106303_bib0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-022-00646-5","article-title":"Vaccination and immunotherapies in neuroimmunological diseases","volume":"18","author":"Winkelmann","year":"2022","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:48:35Z","timestamp":1741841315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"alternative-id":["S2211034825000471"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106303","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The CXCL13 index biomarker predicts success or failure of moderate-efficacy disease-modifying therapies in multiple sclerosis; A real-world study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106303"}}